Manufacturing: Page 12
-
FDA reports first drug shortage due to coronavirus impact
Supplies of the drug, which the FDA did not identify, ran short as a result of issues at a site that produces the active ingredient. Other options are available, the agency said.
By Ned Pagliarulo • Updated March 2, 2020 -
As shortages draw spotlight, Sanofi to spin out drug ingredient business
The new company will launch with significant size, employing 3,100 and drawing from a network of six factories across Europe.
By Ned Pagliarulo • Feb. 24, 2020 -
With supply tight, Novartis readies gene therapy plant for production
Bringing the facility in Durham, North Carolina, online is a critical step for the Swiss pharma's plans to expand the market for Zolgensma, its gene therapy for spinal muscular atrophy.
By Ned Pagliarulo • Feb. 21, 2020 -
WuXi Vaccines inks $3B manufacturing deal with 'global vaccine leader'
Set to last 20 years, the contract between Wuxi and an unidentified vaccine maker calls for the Chinese CDMO to build a dedicated production plant.
By Kristin Jensen • Updated Feb. 21, 2020 -
Audentes to spend $110M on new gene therapy plant in North Carolina
The biotech, which was bought last year by Astellas, joins Pfizer, Bluebird bio and AveXis in choosing to locate gene therapy manufacturing in the state.
By Ned Pagliarulo • Feb. 18, 2020 -
Jacob Bell/BioPharma Dive
FDA monitoring impact of coronavirus outbreak on medical product supply
The agency postponed drug and device inspections in China that were scheduled for February, limiting its oversight of a key country in the medical supply chain.
By Nick Paul Taylor • Feb. 18, 2020 -
In turnaround bid, Teva tries to wring more savings out of manufacturing
The generic maker's push to reduce manufacturing costs follows a restructuring that's saved $3 billion but resulted in layoffs for thousands of employees.
By Kristin Jensen • Feb. 13, 2020 -
Lonza resuming production as coronavirus spread threatens manufacturers
The Swiss contractor briefly extended holiday plant closures in China in response to the outbreak, which has also disrupted Airbus and Hyundai.
By Kristin Jensen • Feb. 6, 2020 -
Catalent, expecting a boom in cell therapy, bids for Masthercell
With biologics driving growth, the contract manufacturer is looking to diversify with a $315 million purchase that hands it a slate of production sites.
By Jacob Bell • Feb. 3, 2020 -
Amgen, Pfizer biosimilar sales pressure top drugs
Competition is heating up for copycats to Roche's top-selling cancer drugs, as the U.S. biosimilar market shows some modest signs of shifting.
By Jonathan Gardner • Jan. 31, 2020 -
German Merck continues manufacturing buildout with $275M investment
The money will go toward a 15,700-square-meter facility, to be called the Biotech Development Center, that's set to be fully operational by 2022.
By Jacob Bell • Jan. 30, 2020 -
AstraZeneca pledges to go 'carbon negative' by 2030
Matching a recent commitment from Microsoft, AstraZeneca says it's stepping up its climate efforts. Recent numbers show the pharma has a ways to go.
By Ned Pagliarulo • Jan. 23, 2020 -
Blue Cross Blue Shield partners with Civica on generic drug mission
The Blue Cross Blue Shield Association, along with 18 affiliate companies, will invest $55 million to create a new unit of the generic drug company.
By Kristin Jensen • Jan. 23, 2020 -
Courtesy of Eli Lilly
Lilly to invest $470M in new North Carolina drug plant
The facility, which will employ more than 400, is part of a broader build-out by Lilly of its manufacturing network.
By Kristin Jensen • Jan. 22, 2020 -
Civica advances drug supply strategy with Thermo Fisher deal
The seven-year partnership will initially focus on nine critical medicines vulnerable to supply chain interruptions.
By Jonathan Gardner • Jan. 16, 2020 -
Nationwide Children's, a gene therapy leader, launches manufacturing spinout
Andelyn Biosciences, named after two children treated with gene therapy at Nationwide, will operate as a for-profit subsidiary of the Ohio-based hospital.
By Ned Pagliarulo • Updated Jan. 15, 2020 -
Courtesy of Eli Lilly
Lilly, Strateos open remote-controlled robotic research lab in San Diego
The lab, which is part of a $90 million investment Lilly made in its San Diego site two years ago, will be accessible to emerging drug discovery companies.
By Kristin Jensen • Jan. 9, 2020 -
Mylan recalls common antacid after detecting carcinogen
The generic drugmaker will pull some nizatidine after tests found low levels of N-nitrosodimethylamine, or NDMA, a probable human carcinogen.
By Andrew Dunn • Jan. 9, 2020 -
Belgian CDMO Ardena gets new private equity owners
The U.K. group GHO Capital Partners bought Ardena, which has expanded in Europe via several acquisitions under the ownership of Mentha Capital.
By Ned Pagliarulo • Jan. 9, 2020 -
Charles River Labs to buy HemaCare for $380M, expanding in cell therapy
The contract researcher expects HemaCare will boost a cell therapy business that earns it about $100 million in annual revenue.
By Kristin Jensen • Dec. 19, 2019 -
Paratek wins US contract to develop anthrax treatment
A BARDA contract will provide Paratek with up to $285 million, some of which would go toward to acquiring the biotech's antibiotic for a national stockpile.
By Kristin Jensen • Dec. 19, 2019 -
Novartis still hasn't solved its CAR-T manufacturing issues
Lingering difficulties in making all Kymriah product to FDA specifications has meant Novartis can't always charge for the cell therapy. New data at ASH could help the pharma's case.
By Ned Pagliarulo • Dec. 11, 2019 -
Novartis partners with Amazon to revamp manufacturing
The collaboration is one of many efforts underway at the Swiss pharma to more effectively manage a sprawling network of clinical and manufacturing sites.
By Kristin Jensen • Dec. 5, 2019 -
Thermo Fisher opens $90M viral vector manufacturing plant in Massachusetts
The CDMO expects to create more than 200 jobs at the site, which is part of the company's plans to expand its gene therapy business.
By Kristin Jensen • Dec. 4, 2019 -
Fujifilm to invest $120M in gene therapy, build center in Texas
The Japan-based company plans to spend $55 million on the center while also outfitting its joint venture with new clean rooms and bioreactors.
By Kristin Jensen • Nov. 21, 2019
Previous
